Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma

Table 3 Univariate analysis for identifying the predictors of survival

Variable	Hazard ratio	95% CI	P value
Treatment regimen (ADM vs DDPH)	0.580	0.325-1.035	0.065
Age ( ≤ 65 yr vs > 65 yr)	1.286	0.741-2.231	0.372
Gender (female vs male)	1.651	0.944-2.888	0.079
Etiology (NBNC vs HBV/HCV)	0.734	0.432-1.246	0.252
Child Pugh classification (A vs B/C)	1.142	0.689-1.891	0.607
TNM classification (I-II vs III-IV)	2.765	1.252-6.106	0.012
Tumor size ( ≤ 3.0 cm vs > 3.0 cm)	2.094	1.161-3.776	0.014
Number of tumors (1-3 vs≥ 4)	2.612	1.535-4.444	0.001
PVTT (Vp0-2 vs Vp3)	4.714	2.520-8.819	< 0.001
Total bilirubin ( ≤ 1.5 mg/dL vs > 1.5 mg/dL)	1.730	0.874-3.422	0.116
Albumin ( ≤ 3.5 g/dL vs > 3.5 g/dL)	0.996	0.603-1.647	0.989
AFP ( ≤ 1000 ng/mL vs > 1000 ng/mL)	1.323	0.528-3.315	0.551
DCP ( ≤ 1000 mAU/mL vs > 1000 mAU/mL)	2.396	1.288-4.459	0.005

DDPH group: Using a suspension of DDPH in lipiodol (LPD); ADM group: With an emulsion of doxorubicin (ADM) with LPD; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NBNC: Negative for hepatitis B surface antigen and HCV antibody; PVTT: Portal vein tumor thrombosis; AFP: α-fetoprotein; DCP: Des-γ-carboxy prothrombin.